Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02096042 · ClinicalTrials.gov registry record · Phase 1
Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT02096042: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT02096042 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02096042, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This clinical research study is made up of 3 phases: a Pilot Phase, Phase 1, and Phase 2. The goal of the Pilot Phase is to learn how safe it is to give the study drug brentuximab vedotin to patients with AML. The goal of Phase 1 is to learn more about the safety of the combination of brentuximab vedotin with azacytidine. The goal of Phase 2 is to learn if the combination of brentuximab vedotin and azacytidine can help to control AML.
Interventions
- DRUG Brentuximab Vedotin
- DRUG 5-Azacytidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2014-04 |
| Est. Completion | 2016-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02096042
The ClinicalTrials.gov registry entry for NCT02096042 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Brentuximab Vedotin is the first listed.
NCT02096042 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02096042 about?
NCT02096042 is a clinical study titled "Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)". This clinical research study is made up of 3 phases: a Pilot Phase, Phase 1, and Phase 2. The goal of the Pilot Phase is to learn how safe it is to give the study drug brentuximab vedotin to patients with AML. The goal of Phase 1 is to learn more about the safety of the combination of brentuximab v...
What is the current status of trial NCT02096042?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2014-04. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02096042?
The interventions under investigation include: Brentuximab Vedotin (DRUG), 5-Azacytidine (DRUG).
Who is sponsoring clinical trial NCT02096042?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.